Do certain diabetes drugs increase the risk of acute kidney injury in patients taking anti-cancer therapies?
2024-10-26
(Press-News.org)
San Diego, CA (October 25, 2024) — Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medications that are increasingly prescribed for patients with type 2 diabetes and congestive heart failure. Reports of GLP-1RA–associated acute kidney injury (AKI) have emerged, but the risk of GLP-1RA–associated AKI among patients on anti-cancer drugs is unclear. Surprisingly, new research suggests that taking GLP-1RA is not associated with an increased risk of AKI in patients receiving anti-cancer therapies. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
For the study, investigators analyzed medical records of patients who were treated with anti-cancer medications including cytotoxic, targeted immunotherapies over a 1-year period.
Among 14,783 patients, 9% were treated with a GLP-1RA while taking ant-cancer drugs. AKI occurred in 7.2% of those exposed to GLP-1RA versus 6.4% of those with no GLP-1RA exposure.
“Given the cardiovascular and anti-diabetic benefits of GLP-IRA, we suggest that these agents can be safely continued during administration of anti-cancer therapy,” said corresponding author Swetha Rani Kanduri, MD, of Ochsner Health. “We invite prospective studies to further elaborate on the effects of GLP1-RA in patients with cancer.”
Study: “Exposure to Glucagon Like Peptide 1 Receptor Agonists (GLP-1RA) Does Not Increase the Risk of AKI Associated with Anti-Cancer Therapy”
Join ASN and approximately 12,000 other kidney professionals from across the globe at Kidney Week 2024 in San Diego, CA. The world's premier nephrology meeting, Kidney Week, provides participants with exciting and challenging opportunities to exchange knowledge, learn the latest scientific and medical advances, and listen to engaging and provocative discussions with leading experts in the field. Early programs begin on October 23, followed by the Annual Meeting from October 24-27. Follow the conversation at #KidneyWk.
About ASN
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge and advocating for the highest quality care for patients. ASN has nearly 21,000 members representing 140 countries. For more information, visit www.asn-online.org and follow us on Facebook, X, LinkedIn, and Instagram.
# # #
END
ELSE PRESS RELEASES FROM THIS DATE:
2024-10-26
San Diego, CA (October 25, 2024) — Prior efforts to identify novel kidney biomarkers as risk factors for chronic kidney disease (CKD) progression have typically evaluated proteins individually, which limits their prognostic power. The National Institute of Diabetes and Digestive and Kidney Diseases’ (NIDDK’s) CKD Biomarkers Consortium of investigators recently developed and tested novel dimensions of kidney health by combining a set of 17 urine and plasma biomarkers that ...
2024-10-26
San Diego, CA (October 25, 2024) — IgA nephropathy (IgAN) is an autoimmune kidney disease driven by immune cells that express a protein called CD38 on their surface. A recent Phase 2 trial revealed that felzartamab, an investigational anti-CD38 monoclonal antibody, helps to reduce proteinuria and maintain patients’ kidney function. Investigators evaluated the molecular mechanisms underlying felzartamab’s potential efficacy in IgAN. The findings will be presented at ASN Kidney Week 2024 October 23– 27.
It is hypothesized that CD38+ cells ...
2024-10-26
San Diego, CA (October 25, 2024) — Sodium-glucose co-transporter 2 (SGLT2) inhibitors reduce the risk of cardiovascular and kidney outcomes in patients with type 2 diabetes, but it is unclear whether their effects differ based on patients’ age. A recent analysis of clinical trial data reveals that the SGLT2 inhibitor canagliflozin benefited patients across all age categories. The findings will be presented at ASN Kidney Week 2024 October 23 – 27.
The analysis pooled individual participant data from the CANVAS Program and CREDENCE trial and assessed efficacy and safety according to baseline age. ...
2024-10-25
The Arctic is warming at three to four times the global average. However, new research suggests the slowing of a key ocean current could reduce projected Arctic warming by up to 2 degrees Celsius by the end of the century.
For years, scientists have warned that unchecked Arctic warming could lead to devastating consequences, threatening wildlife and ushering in an era of more frequent and extreme weather events. Amid concerns for these types of outcomes, a study led by UC Riverside offers some limited relief.
The study, published in the Proceedings of the National Academy of Sciences, examined ...
2024-10-25
San Diego, CA (October 25, 2024) — A recent analysis reveals that the number of chronic kidney disease (CKD) cases in women around the globe nearly tripled in the past three decades. Also, type 2 diabetes and hypertension were the leading causes of CKD-related deaths in women. The research will be presented at ASN Kidney Week 2024 October 23– 27.
The analysis drew from the Global Burden of Disease study 2021, a comprehensive effort to quantify health loss across the world over time. The study includes information from 204 countries and territories.
From 1990 to 2021, the average annual percentage ...
2024-10-25
Ever had an itchy nose or, worse, an unreachable spot on your back that drives you mad? Now imagine an itch that refuses to go away, no matter how hard or long you scratch. That persistent itch, or pruritus, may actually be one of the skin’s first lines of defense against harmful invaders, according to neuroimmunologist Juan Inclan-Rico of the University of Pennsylvania.
“It’s inconvenient, it’s annoying, but sensations like pain and itch are crucial. They’re ever-present, especially when it comes to skin infections,” says Inclan-Rico, a postdoctoral researcher in the Herbert Lab at ...
2024-10-25
It feels like narcissism is everywhere these days: politics, movies and TV, sports, social media. You might even see signs of it at work, where it can be particularly detrimental. Is it possible to keep a workplace free of destructive, manipulative egotists?
More and more organizations have come to San Francisco State University’s experts in organizational psychology asking for help doing just that. In response, University researchers developed a tool for job interviews to assess narcissistic grandiosity among potential job candidates. San Francisco State Psychology Professors Kevin Eschleman and Chris ...
2024-10-25
You have likely not spent much time thinking about the uterus of the fruit fly, Drosophila melanogaster. But then, neither have most scientists, even though Drosophila is one of the most thoroughly studied lab animals. Now a team of biologists at the University of California, Davis, has taken the first deep look at the Drosophila uterus and found some surprises, which could have implications not just for understanding insect reproduction and potentially, pest control, but also for understanding fertility in humans.
The work is published Oct. 25 in Proceedings of the National Academy of Sciences.
Drosophila have been a favorite subject for ...
2024-10-25
A recent commentary published in The Lancet journal highlights the critical importance of skeletal muscle mass in the context of medically induced weight loss, particularly with the widespread use of GLP-1 receptor agonists. These medications, celebrated for their effectiveness in treating obesity, have raised concerns regarding the potential for substantial muscle loss as part of the weight loss process.
Dr. Steven Heymsfield, professor of metabolism and body composition, and Dr. M. Cristina Gonzalez, adjunct and visiting professor in metabolism-body composition, both of Pennington Biomedical Research Center, joined colleagues Dr. Carla Prado of the University ...
2024-10-25
NYU Tandon School of Engineering's Urban Future Lab named the winners of its 2024 Future Resilience and Future Solutions prizes, at its 8th annual Urban Future Summit on October 24, 2024 at the Brooklyn Navy Yard in New York City. Through the generous support of The New York Community Trust, MUFG Bank, Mitsubishi Corporation (Americas), the Urban Future Lab continues to catalyze groundbreaking solutions for the climate crisis and this year, they’ve expanded their focus to include adaptation as a critical piece of the puzzle.
After an afternoon of pitches, the jury, comprised of industry experts and ...
LAST 30 PRESS RELEASES:
[Press-News.org] Do certain diabetes drugs increase the risk of acute kidney injury in patients taking anti-cancer therapies?
